PROC
vs
S&P 500
PROC
S&P 500
Over the past 12 months, PROC has underperformed S&P 500, delivering a return of -58% compared to the S&P 500's +14% growth.
Stocks Performance
PROC vs S&P 500
Performance Gap
PROC vs S&P 500
Performance By Year
PROC vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Procaps Group SA
Glance View
Procaps Group SA develops pharmaceutical and nutraceutical solutions, medicines, and hospital supplies. The firm develops, manufactures and sells prescription drugs and products that are differentiated by their combinations and pharmaceutical forms, as well as nutritional supplements which include omega 3 fish oils and high-potency clinical compounds. The company operates its business through 5 units which are Diabetrics, Farma Procaps, Softi Gel, Vital Care, and Clinical Specialties. Diabetrics provides diabetes solutions. Farma procaps formulates, manufactures and markets branded prescription drugs in Latin America. Softi Gel provides contract drug development and manufacturing services to third party pharmaceutical companies. Vital Care develops, manufactures and markets consumer healthcare products. Clinical Specialties develops, manufactures and markets complex drugs.